datetime,headline,summary,related,lang,source
2020-11-24 08:00:00-05:00,bluebird bio Announces Live Webcast to Review Clinical Data Presented at the American Society of Hematology (ASH) Annual Meeting,"CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) today announced that the company will host a live webcast on December 7, 2020 at 7:00 p.m. ET to review clinical data presented at the 62nd American Society of Hematology Annual Meeting and Exposition. Investors may listen to the call by dialing (844) 825-4408 from locations in the United States or +1 (315) 625-3227 from outside the United States. Please refer to conference ID number 3493595. To access the live webcast of blue","BLUE,BLE",en,Business Wire
2020-11-21 23:11:35-05:00,"SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of bluebird bio, Inc. - BLUE - Stocks News Feed","NEW YORK, Nov. 21, 2020 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of bluebird bio, Inc. (“bluebird” or the “Company”) (NASDAQ:BLUE). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. The investigation concerns whether bluebird and certain of its officers and/or directors have engaged… Read More »SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of bluebird bio, Inc. – BLUE","BLUE,BLE",en,Stocks News Feed
2020-11-20 04:16:36-05:00,"Global Gene Therapy for Blood Disorders Market Assessment 2020 - Key Player such as Biomarin Therapeutics, Spark Therapeutics, Shire, bluebird bio, Inc., CRISPR Therapeutics, Medgenics, OrphageniX and many more.","InsightAce Analytic Pvt. Ltd. announces the release of the market assessment report on “Global Gene Therapy for Blood Disorders Market Assessment – Revenue (US$ Mn) Forecast Till 2030” Request for Sample Pages: https://www.insightaceanalytic.com/report-details/global-gene-therapy-for-blood-disorders-market-assessment/ According to the latest research by InsightAce Analytic,","BLUE,BLE",en,OpenPR
2020-11-10 08:00:00-05:00,bluebird bio Announces November Investor Events,"CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will participate in the following upcoming investor conferences: Cowen 2020 IO Next Summit, Friday, November 13, at 11:15 am ET Barclays Gene Editing & Gene Therapy Summit, Monday, November 16, at 7:45 am ET To access the live webcasts of bluebird bio’s presentations, please visit the “Events & Presentations” page within the Investors & Media section of the bluebi","BLUE,BLE",en,Business Wire
2020-11-08 12:47:42-05:00,"The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions","Biotech stocks turned around with the broader market in the week ended Nov. 6, as investors warmed to the idea of a split Congress and a change of guard at the White House. The week witnessed a flurry of earnings from several smid-cap companies. Bluebird bio Inc. (NASDAQ: BLUE ) shares came under pressure after it announced a push back in the timeline for the regulatory filing for its gene therapy to treat sickle cell disease. Biogen Inc. (NASDAQ: BIIB ) was also in the news over an FDA roadblock regarding its Alzheimer's drug aducanumab. On the M&A front, Merck & Co. Inc. (NYSE: MRK ) announced a $2.75 billion deal to buy oncology-focused biopharma VelosBio Inc. Here are the key biotech events to watch out for in the unfolding week: Conferences American College of Rheumatology, or ACR, Convergence 2020: Nov. 5-9 Credit Suisse 29th Annual Virtual Healthcare Conference: Nov. 9-10 35th Annual Meeting of The Society for Immunotherapy of Cancer, or SITC: Nov. 9-14 American Academy of Ophthalmology, or AAO, 2020 Virtual meeting: Nov.","BNTX,BLUE,BLE",en,Benzinga
2020-11-06 04:07:49-05:00,Merrill Lynch Stick to Their Buy Rating for bluebird bio,Merrill Lynch Stick to Their Buy Rating for bluebird bio,"BLUE,BLE",en,Investing.com
2020-11-05 12:14:00-05:00,bluebird bio Earnings and Growth Analysis : Stock market Insights & financial analysis,"bluebird bio announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…","BLUE,BLE",en,Stock Market Daily
2020-11-05 11:23:16-05:00,Why Bluebird Bio's Stock Is Trading Lower Today,Bluebird Bio (NASDAQ: BLUE ) shares are trading lower on Thursday after the company reported third-quarter earnings results. BMO also downgraded the stock from Outperform to Market Perform with a price target of $56 per share. Bluebird Bio is a clinical-stage biotechnology company that … Full story available on Benzinga.com,"BLUE,BLE",en,Benzinga
2020-11-05 10:11:50-05:00,Bluebird bio's stock plunges after submission delay of sickle cell disease treatment,"Shares of Bluebird bio Inc. undefined traded 15.1% into the red in morning trading Thursday, after the gene therapy company pushed back the U.S. submission…","BLUE,BLE",en,MarketWatch
2020-11-05 08:38:15-05:00,"Global Gene Therapy Market with COVID-19 Impact Analysis, Top Companies Novartis AG, Gilead Sciences Inc, Spark Therapeutics LLC, Bluebird Bio, Market Opportunities, Growth, Forecast To 2026",Global Gene Therapy Market is expected to grow at a higher rate during the forecast period 2020-2026. A Global Research Report called Gene Therapy Market was recently published by Market Research Inc. to provide guidance for the business. The report,"BLUE,BLE",en,OpenPR
2020-11-05 07:54:15-05:00,"The Daily Biotech Pulse: Bluebird Bio Plunges On Regulatory Filing Delay, Synlogic Soars On Study Initiation, European Label Expansion For Vertex, Merck Goes Shopping","Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 4) Abbott Laboratories (NYSE: ABT ) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) Anavex Life Sciences Corp (NASDAQ: AVXL ) Aptevo Therapeutics Inc (NASDAQ: APVO ) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) Ascendis Pharma A/S (NASDAQ: ASND ) Athira Pharma Inc (NASDAQ: ATHA ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) Bio-Rad Laboratories, Inc. Class B Common Stock (NYSE: BIO ) Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN ) BioLife Solutions Inc (NASDAQ: BLFS ) Cardiff Oncology Inc (NASDAQ: CRDF ) Denali Therapeutics Inc (NASDAQ: DNLI ) - moved in sympathy with Biogen Inc (NASDAQ: BIIB ) Guardant Health Inc (NASDAQ: GH ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) Hologic, Inc. (NASDAQ: HOLX ) Idera Pharmaceuticals Inc (NASDAQ: IDRA ) Inspire Medical Systems Inc (NYSE: INSP ) Immunovant Inc (NASDAQ: IMVT ) Intellia Therapeutics Inc (NASDAQ: NTLA ) Jazz Pharmaceuticals PLC (NASDAQ: JAZZ ) Kodiak Sciences Inc (NASDAQ: KOD ) Laboratory Corp.","BLFS,BLUE,BLE,BMY",en,Benzinga
2020-11-05 07:30:00-05:00,bluebird bio to Present Data from Gene and Cell Therapy Programs During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition,"CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) announced today that data from its gene and cell therapy programs for sickle cell disease (SCD), transfusion-dependent beta-thalassemia (TDT) and multiple myeloma (MM) will be presented, including seven oral presentations, at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, taking place virtually from December 5-8, 2020. Updated results from patients in Group C of the company’s Phase 1/2 HGB-206 stu","BLUE,BLE",en,Business Wire
2020-11-05 06:38:15-05:00,"Global Gene Therapy Products Market 2020 New Informative Study || Leading Players –Anchiano Therapeutics, bluebird bio, Inc., CELGENE CORPORATION",Global Gene Therapy Products Market research report has been produced with the systematic gathering of market information for industry. All this information is supplied in such a way that it properly gives explanation of various facts and figures to the,"BLUE,BLE",en,OpenPR
2020-11-05 04:56:06-05:00,BLUEBIRD BIO - Bullischer Ausbruch,Ralph Nelson Elliott liebte nachhaltige Impulauffächerungen und schenkte diesen Werten eine besondere Aufmerksamkeit.,"BLUE,BLE",de,GodmodeTrader
2020-11-04 16:05:00-05:00,bluebird bio Reports Third Quarter 2020 Financial Results and Highlights Operational Progress,"CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) today reported financial results and business highlights for the third quarter ended September 30, 2020 and shared recent operational progress. “While 2020 continues to present unprecedented challenges, bluebird has continued to advance our innovative cell and gene therapy programs. Looking to 2021 and beyond, this is a catalyst-rich period for bluebird as we are on the cusp of multiple approvals in the U.S. and EU,” said Nick","BLUE,BLE",en,Business Wire
2020-10-22 08:39:51-05:00,"CAR T Cell Therapy Market Future Opportunities, Market Analysis & Outlook To 2026 | Novartis International AG, Kite Pharma, Inc. (Gilead Sciences, Inc.), Juno Therapeutics (Celgene Corporation), Bluebird Bio, Inc. (Celgene Corporation)","The “CAR T Cell Therapy Market” Research Report is a resource, which provides current as well as upcoming technical and financial details of the industry to 2027. This report gives you so important and essentials data of Market size, share,","BLUE,BLE",en,OpenPR
2020-10-21 23:02:54-05:00,bluebird bio (NASDAQ:BLUE) Earns Buy Rating from Analysts at Mizuho,"Mizuho started coverage on shares of bluebird bio (NASDAQ:BLUE) in a research note published on Monday, Anlyst Ratings reports. The brokerage issued a buy rating and a $123.00 price target on the biotechnology company’s stock. A number of other analysts also recently weighed in on BLUE. Bank of America decreased their price target on shares […]","BLUE,BLE",en,Dispatch Tribunal
2020-10-21 03:04:44-05:00,"Zacks: Analysts Anticipate bluebird bio, Inc. (NASDAQ:BLUE) Will Announce Earnings of -$3.09 Per Share","Wall Street brokerages expect that bluebird bio, Inc. (NASDAQ:BLUE) will report ($3.09) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Nine analysts have provided estimates for bluebird bio’s earnings, with the lowest EPS estimate coming in at ($3.81) and the highest estimate coming in at ($0.98). bluebird bio reported earnings […]","BLUE,BLE",en,Stock Observer
2020-10-21 01:36:51-05:00,bluebird bio (NASDAQ:BLUE) Now Covered by Mizuho,"Mizuho began coverage on shares of bluebird bio (NASDAQ:BLUE) in a report released on Monday, AR Network reports. The brokerage set a “buy” rating and a $123.00 price target on the biotechnology company’s stock. Mizuho’s price objective would suggest a potential upside of 123.64% from the stock’s current price. Several other analysts also recently weighed […]","BLUE,BLE",en,Zolmax News
2020-10-20 07:57:03-05:00,"Top Analyst Upgrades and Downgrades: AEP, Apache, AT&T, Bluebird, Fortinet, Intel, IBM, Kinder Morgan, New Residential, Snap, Verizon and More – 24/7 Wall St.","Tuesday's top analyst upgrades and downgrades included American Electric Power, Apache, AT&T, ConocoPhillips, Bluebird Bio, Fortinet, Intel, IBM, Kinder Morgan, New Residential Investment, Snap and Verizon.","BLUE,BLE",en,24/7 Wall street
2020-10-19 20:07:01-05:00,bluebird bio (NASDAQ:BLUE) Coverage Initiated by Analysts at Mizuho,"Mizuho started coverage on shares of bluebird bio (NASDAQ:BLUE) in a research note released on Monday morning, The Fly reports. The firm issued a buy rating on the biotechnology company’s stock. Several other brokerages also recently commented on BLUE. Oppenheimer assumed coverage on shares of bluebird bio in a research report on Monday, August 31st. […]","BLUE,BLE",en,Daily Political
2020-10-13 08:13:01-05:00,"CAR T Cell Therapy Market size (sales, revenue) Industry Forecast by Regions, Countries and Top Players from 2018 to 2026 | Novartis International AG, Kite Pharma, Inc. (Gilead Sciences, Inc.), Juno Therapeutics (Celgene Corporation), Bluebird Bio, Inc. (",CMI Research added a comprehensive research document of 200+ pages on the ‘CAR T Cell Therapy Market’ with detailed insights on growth factors and strategies. It describes the current situation of the CAR T Cell Therapy market by examining in-depth,BLE,en,OpenPR
2020-10-02 04:00:00-05:00,"bluebird bio Announces European Medicines Agency’s Acceptance of Marketing Authorization Application (MAA) for elivaldogene autotemcel (eli-cel, Lenti-D™) Gene Therapy for Cerebral Adrenoleukodystrophy (CALD)","CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio announces EMA's acceptance of Marketing Authorization Application (MAA) for elivaldogene autotemcel gene therapy for CALD.",BLE,en,Business Wire
2020-09-28 07:00:00-05:00,bluebird bio to Present at Jefferies Cell Therapy Virtual Summit,"CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will participate in the Jefferies Cell Therapy Virtual Summit, Tuesday, October 6, at 2:00 p.m. ET. To access the live webcast of bluebird bio’s presentation, please visit the “Events & Presentations” page within the Investors & Media section of the bluebird bio website at http://investor.bluebirdbio.com. Replays of the webcast will be available on the bluebird bio we",BLE,en,Business Wire
2020-09-23 04:00:00-05:00,bluebird bio’s LentiGlobin™ for Sickle Cell Disease Gene Therapy (bb1111) Granted Priority Medicines (PRIME) Designation by European Medicines Agency,"CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) announced today that its investigational treatment for sickle cell disease (SCD), LentiGlobin™ for SCD gene therapy (bb1111), was granted eligibility to the Priority Medicines (PRIME) program by the European Medicines Agency (EMA). The EMA’s PRIME initiative provides enhanced support and increased interaction to companies, with the goal of optimizing development plans and speeding regulatory evaluations to potentially bring in","BLUE,BLE",en,Business Wire
2020-09-09 05:09:00-05:00,Is bluebird bio Stock a Buy?,bluebird bio hasn't performed well in the stock market of late. Do the biotech's recent woes make this a good opportunity for investors to buy its shares?,"BLUE,BLE",en,The Motley Fool
2020-09-02 07:00:00-05:00,bluebird bio Announces September Investor Events,"CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will participate in the following upcoming investor conferences: 2020 Wells Fargo Virtual Healthcare Conference, Thursday, September 10, at 4:00 pm ET Morgan Stanley 18th Annual Global Healthcare Conference, Tuesday, September 15, at 1:15 pm ET BofA Global Healthcare Conference 2020, Friday, September 18, at 10:05 am ET To access the live webcasts of bluebird bio’s presentati","BLUE,BLE",en,Business Wire
2020-08-29 05:30:00-05:00,"bluebird bio Presents New Results from Clinical Development Program of elivaldogene autotemcel (eli-cel, Lenti-D™) Gene Therapy for Cerebral Adrenoleukodystrophy (CALD), Including Updated Long-Term Data, at the 46th Annual Meeting of the EBMT","CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) announced updated results from the clinical development program for its investigational elivaldogene autotemcel (eli-cel, Lenti-D™) gene therapy in patients with cerebral adrenoleukodystrophy (CALD), including long-term results from the Phase 2/3 Starbeam study (ALD-102/LTF-304) and data from the Phase 3 ALD-104 study. These data were presented today at the 46th Annual Meeting of the European Society for Blood and Marrow Trans","BLUE,BLE",en,Business Wire
2020-08-18 13:41:03-05:00,bluebird bio : Corporate Presentation Q3 2020 | MarketScreener,"Actively engaging to enable access & value-based payment over time at launch Policy - Focused on enabling value-based payment over time in commercial and for Medicaid… | August 18, 2020","BLUE,BLE",en,MarketScreener
2020-08-11 06:01:00-05:00,bluebird bio Appoints Denice Torres to Board of Directors,"CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) today announced that it has appointed Denice Torres to its Board of Directors. “We’re excited to welcome Denice to the Board to help guide bluebird as we reach the next stage in our evolution,” said Nick Leschly, chief bluebird. “Denice brings valuable perspective and exceptional industry insights based on over 25 years of executive management experience in pharmaceuticals, medical device and consumer healthcare for global org","BLUE,BLE",en,Business Wire
2020-08-06 10:42:47-05:00,Why Bluebird Bio's Stock Is Trading Higher Today,Bluebird Bio (NASDAQ: BLUE ) shares are trading higher on Thursday after the company reported second-quarter EPS and sales results up from last year. Wedbush also maintained its Outperform rating on the stock. Bluebird Bio is a clinical-stage biotechnology company that develops gene therapies … Full story available on Benzinga.com,"BLUE,BLE",en,Benzinga
2020-08-06 06:42:00-05:00,Why Bluebird Bio's Stock Is Trading Higher Today,Bluebird Bio (NASDAQ: BLUE) shares are trading higher on Thursday after the company reported second-quarter EPS and sales results up from last year. Wedbush …,"BLUE,BLE",en,Benzinga
2020-08-05 15:10:00-05:00,bluebird bio Reports Second Quarter 2020 Financial Results and Recent Operational Progress,"CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) today reported financial results and business highlights for the second quarter ended June 30, 2020 and shared recent operational progress. “I am incredibly proud of the progress made at bluebird this quarter, and the way in which our employees have continued to execute on behalf of patients in the midst of an ongoing global pandemic,” said Nick Leschly, chief bluebird. “It is especially gratifying that despite these challenge","BLUE,BLE",en,Business Wire
2020-07-31 07:00:00-05:00,bluebird bio Announces August Investor Event,"CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) today announced members of the management team will participate in the Canaccord Genuity 40th Annual Growth Conference, Wednesday, August 12, at 10:30 a.m. ET. To access the live webcast of bluebird bio’s presentation, please visit the “Events & Presentations” page within the Investors & Media section of the bluebird bio website at http://investor.bluebirdbio.com. A replay of the webcast will be available on the bluebi","BLUE,BLE",en,Business Wire
2020-07-30 03:09:00-05:00,"The Daily Biotech Pulse: Bristol-Myers, Bluebird Bio Resubmit Multiple Myeloma Drug BLA, FSD To Close Medicinal Cannabis Business, Hologic's Blowout Quarter","Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 29) Abbott Laboratories (NYSE: ABT) ABIOMED, Inc. (NASDAQ: ABMD) Adamis Pharmaceuticals Corp …","BLUE,BLE",en,Benzinga
2020-07-29 15:16:00-05:00,"Bristol Myers Squibb and bluebird bio Announce Submission of Biologics License Application (BLA) to FDA for Idecabtagene Vicleucel (Ide-cel, bb2121) for Adults with Relapsed and Refractory Multiple Myeloma","PRINCETON, N.J., & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BLUE #BMS--BMS and bluebird bio Announce Submission of Biologics License Application (BLA) to FDA for Idecabtagene Vicleucel (Ide-cel, bb2121)…","BLUE,BLE,BMY",en,Business Wire
2020-06-21 07:54:20-05:00,"Bluebird Bio (BLUE) Reports Q1 Loss, Tops Revenue Estimates","Bluebird (BLUE) delivered earnings and revenue surprises of 7.61% and 147.26%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?","BLUE,BLE",en,Zacks Investment
2020-06-18 13:02:03-05:00,BlackRock Municipal Income Trust II : Announces Board Approval of Municipal Closed-End Fund Reorganizations | MarketScreener,"Contact: 1-800-882-0052 BlackRock Announces Board Approval of Municipal Closed-End Fund Reorganizations New York, June 16, 2020 - BlackRock… | June 18, 2020","BLK,BLE",en,MarketScreener
2020-06-05 04:35:00-05:00,"bluebird bio's Shares March Higher, Can It Continue?","As of late, it has definitely been a great time to be an investor in bluebird bio.","BLE,BLUE",en,Zacks Investment Research
2020-06-03 15:05:00-05:00,bluebird bio Announces That Its 2020 Annual Meeting of Stockholders Will Be Held in Virtual Format,"CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) today announced that, due to the public health and safety concerns related to the novel coronavirus (COVID-19) pandemic, to support the health and well-being of its directors, employees and stockholders, the location of the Company’s 2020 Annual Meeting of Stockholders (including any adjournments or postponements, the “Annual Meeting”) has been changed to a virtual format only. As previously announced, the Annual Meeting will","BLE,BLUE",en,Business Wire
2020-05-28 07:00:00-05:00,bluebird bio Announces Live Webcast of EHA Data Review and June Investor Events,"CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) today announced that the company will host a live webcast to review new data presented at the European Hematology Association (EHA) Annual Meeting on Friday, June 12 at 8:00 am ET. Investors may listen to the call on June 12, 2020 at 8:00 am ET by dialing (844) 825-4408 from locations in the United States or +1 (315) 625-3227 from outside the United States. Please refer to conference ID number 2796099. In addition, members of","BLE,BLUE",en,Business Wire
2020-05-19 06:19:24-05:00,"Bluebird Prices New Shares At $55, Seeks To Raise $500 Million","Bluebird Bio (BLUE) priced an offering of 9.09 million shares of its common stock at $55 each, the company said late on Monday. The post Bluebird Prices New Shares At $55, Seeks To Raise $500 Million appeared first on Smarter Analyst .","BLE,BLUE",en,Smarter Analyst
2020-05-18 20:32:00-05:00,bluebird bio Announces Pricing of Public Offering of Common Stock,"CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) today announced the pricing of an underwritten public offering of 9,090,910 shares of its common stock at a public offering price of $55.00 per share, before underwriting discounts. In addition, bluebird bio has granted the underwriters a 30-day option to purchase up to an additional 1,363,636 shares of common stock. All of the shares in the offering are to be sold by bluebird bio. Goldman Sachs & Co. LLC, BofA Securities","BLE,BLUE",en,Business Wire
2020-05-18 06:08:32-05:00,Bluebird Bio's stock falls after proposed public stock offering,"Shares of Bluebird Bio Inc. undefined fell 2.9% in premarket trading Monday, after the gene therapy company said it was proposing a public offering of $400…","BLE,BLUE",en,MarketWatch
2020-05-18 06:00:00-05:00,bluebird bio Announces Proposed Public Offering of Common Stock,"bluebird bio, Inc. (Nasdaq: BLUE) today announced that it has commenced an underwritten public offering of $400 million of its common stock. bluebird","BLE,BLUE",en,Business Wire
2020-05-13 16:00:00-05:00,Bristol Myers Squibb and bluebird bio to Present Updated Positive Results from Pivotal KarMMa Study of Ide-cel in Relapsed and Refractory Multiple Myeloma Patients at ASCO20,"PRINCETON, N.J., & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BMY #ASCO20--BMS & bluebird bio to Present Updated Positive Results from Pivotal KarMMa Study of Ide-cel in Relapsed and Refractory Multiple Myeloma Patients","BMY,BLE,BLUE",en,Business Wire
2020-05-13 09:41:42-05:00,"Bristol-Myers, Bluebird Bio to Resubmit FDA Bid for Myeloma Treatment",The FDA declines to move forward on the application for the companies' experimental multiple myeloma treatment.,"BLE,BLUE",en,The Street
2020-05-13 08:08:12-05:00,"Top Analyst Upgrades and Downgrades: Bluebird Bio, Ciena, CommVault, Dollar General, JD.com, Kroger, Nucor, Target, Walmart and More",No summary available.,"BLE,BLUE",en,24/7 Wall street
2020-05-13 06:40:30-05:00,"The Daily Biotech Pulse: Gilead Signs Manufacturing Deal For Remdesivir, Bristol-Myers Gets Refuse-To-File Letter","Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 12) Acceleron Pharma Inc (NASDAQ: XLRN )(reacted to its first-quarter results) Allogene Therapeutics Inc (NASDAQ: ALLO ) Arcturus Therapeutics Ltd (NASDAQ: ARCT ) Arvinas Inc (NASDAQ: ARVN ) Ascendis Pharma A/S (NASDAQ: ASND ) AtriCure Inc. (NASDAQ: ATRC ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) BioSig Technologies Inc (NASDAQ: BSGM ) BIO-TECHNE Corp (NASDAQ: TECH ) BioXcel Therapeutics Inc (NASDAQ: BTAI )(announced its first-quarter results) Black Diamond Therapeutics Inc (NASDAQ: BDTX )(reacted to its first-quarter results) ChemoCentryx Inc (NASDAQ: CCXI )(reacted to its first-quarter results) Cytokinetics, Inc. (NASDAQ: CYTK ) CytomX Therapeutics Inc (NASDAQ: CTMX ) Cytosorbents Corp (NASDAQ: CTSO )(announced European approval for Cytosorb) Emergent Biosolutions Inc (NYSE: EBS ) Exelixis, Inc. (NASDAQ: EXEL ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Halozyme Therapeutics, Inc.","BLE,BLUE",en,Benzinga
2020-05-13 05:59:00-05:00,"Bristol Myers Squibb and bluebird bio Provide Regulatory Update on Idecabtagene Vicleucel (ide-cel, bb2121) for the Treatment of Patients with Multiple Myeloma","PRINCETON, N.J., & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BMY #BMS--BMS and bluebird bio Provide Regulatory Update on Idecabtagene Vicleucel (ide-cel, bb2121) for the Treatment of Patients with Multiple Myeloma","BMY,BLE,BLUE",en,Business Wire
2020-05-11 06:35:00-05:00,bluebird bio Announces Amended BCMA CAR-T Collaboration Agreement,"CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) today announced that it has amended its existing co-promotion/co-development agreement with Bristol Myers Squibb (BMS) to enable the companies to focus their efforts on efficient commercialization of idecabtagene vicleucel (ide-cel; bb2121) in the U.S., the companies’ lead investigational B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell immunotherapy, currently in review with the FDA. “Under our","BMY,BLE,BLUE",en,Business Wire
2020-05-11 06:00:00-05:00,bluebird bio Provides Operational and Business Update and Reports First Quarter 2020 Financial Results,"CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) today reported financial results and business highlights for the first quarter ended March 31, 2020 and provided an operational update. “We remain grounded in our core values and priorities: our patients, our people, our community and our business,” said Nick Leschly, chief bluebird. “This quarter, we successfully submitted the ide-cel BLA with our partners at BMS and I am pleased to announce today that we have alignment with","BLE,BLUE",en,Business Wire
2020-05-08 08:55:00-05:00,Is a Surprise Coming for bluebird bio (BLUE) This Earnings Season?,bluebird bio (BLUE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.,"BLE,BLUE",en,Zacks Investment Research
2020-05-08 06:30:00-05:00,bluebird bio to Present Updated Results From Pivotal Phase 2 KarMMa Study of Ide-cel in Relapsed and Refractory Multiple Myeloma During ASCO20 Virtual Scientific Program,"CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) announced today that updated results from the pivotal Phase 2 KarMMa study evaluating the efficacy and safety of idecabtagene vicleucel (ide-cel; bb2121), an investigational B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell therapy, in heavily pre-treated patients with relapsed and refractory multiple myeloma (RRMM) will be presented, in partnership with Bristol Myers Squibb, during the American","BMY,BLE,BLUE",en,Business Wire
2020-05-05 12:33:59-05:00,"These 22 well-known companies have a rare opportunity to soon get acquired due to the coronavirus crisis, BTIG says","Private-equity firms are sitting on an estimated $1.5 trillion in cash that can be used to acquire companies. The coronavirus crisis has cheapened the valuations of many popular companies and made them potential targets for deals. BTIG's Julian Emanuel identified 22 such targets that have been supported by private equity or venture-capital money in the past. Click here for more BI Prime stories . Warren Buffett is not the only investor who is hesitating to buy companies in this environment. The coronavirus crisis has cast a large shadow of uncertainty on the future of asset prices and, more broadly, how the global economy will function. For this reason, Buffett's Berkshire Hathaway is sitting on $128 billion in cash and waiting for the right opportunity. Like Buffett, private-equity (PE) firms also have reserves of dry powder — $1.5 trillion in total, according to BTIG's estimates. ""The question of 'what to buy?' for PE is more vexing than usual, given the elevated uncertainty,"" said Julian Emanuel, the chief equity and derivatives strategist at BTIG, in a recent note. ""Yet this uncertainty is what has consistently created opportunity for patient, long-term investors over the last two generations."" The one thing all crises have in common is that they end.","BLE,BLUE",en,Business Insider
2020-04-29 07:00:00-05:00,bluebird bio Announces First Quarter 2020 Earnings Conference Call and May Investor Event,"CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) today announced it will hold a conference call to discuss first quarter 2020 financial results and business updates on Monday, May 11 at 8:00 am ET. Investors may listen to the call on May 11, 2020 at 8:00 am ET by dialing (844) 825-4408 from locations in the United States or +1 (315) 625-3227 from outside the United States. Please refer to conference ID number 3355158. In addition, members of the management team will particip","BLE,BLUE",en,Business Wire
2020-04-20 07:51:00-05:00,bluebird bio (BLUE) Catches Eye: Stock Jumps 6%,"bluebird bio (BLUE) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.","BLE,BLUE",en,Zacks Investment Research
2020-04-03 17:34:00-05:00,7 Promising Biotech Stocks in a Postpandemic World,"Casdin Capital’s Eli Casdin highlights seven promising life-sciences stocks, including bluebird bio, Invitae, and Crispr Therapeutics","BLE,BLUE",en,Barron's
2020-03-31 05:59:00-05:00,"Bristol Myers Squibb and bluebird bio Announce Submission of Biologics License Application (BLA) for Anti-BCMA CAR T Cell Therapy Idecabtagene Vicleucel (Ide-cel, bb2121) to FDA","PRINCETON, NJ. & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- #celltherapy--Bristol Myers Squibb & bluebird bio Announce Submission of BLA for Anti-BCMA CAR T Cell Therapy Idecabtagene Vicleucel (Ide-cel, bb2121) to FDA","BLE,BLUE",en,Business Wire
2020-03-27 11:45:00-05:00,Global Hematopoietic Stem Cells Transplantation (HSCT) Market 2020-2024 | Evolving Opportunities with AllCells Corp. and bluebird bio Inc. | Technavio,LONDON--(BUSINESS WIRE)-- #HematopoieticStemCellsTransplantationHSCTMarket--The hematopoietic stem cells transplantation market size has the potential to grow by USD 4.64 billion during 2020-2024,"BLE,BLUE",en,Business Wire
2020-03-26 06:30:00-05:00,"bluebird bio Provides Assessment of Impact of COVID-19, Update on Business Operations and Clinical Program Development","CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) today provided an update in response to the global COVID-19 pandemic. The company has taken steps to ensure the safety of its patients and employees, while working to ensure the sustainability of its business operations as this unprecedented situation continues to evolve. “The COVID-19 pandemic has created new challenges for bluebird, the broader biotech community, and society as a whole. During this unprecedented time, we rem","BLE,BLUE",en,Business Wire
2020-03-13 06:52:53-05:00,"The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings","Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 12.) Masimo Corporation (NASDAQ: MASI ) Down In The Dumps (Biotech stocks that hit 52-week lows March 12.) Abbott Laboratories (NYSE: ABT ) ABIOMED, Inc. (NASDAQ: ABMD ) Acasti Pharma Inc (NASDAQ: ACST ) Accelerate Diagnostics Inc (NASDAQ: AXDX ) AcelRx Pharmaceuticals Inc (NASDAQ: ACRX ) Achieve Life Sciences Inc (NASDAQ: ACHV ) Acorda Therapeutics Inc (NASDAQ: ACOR ) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Adamis Pharmaceuticals Corp (NASDAQ: ADM ) Adaptive Biotechnologies Corp (NASDAQ: ADPT ) ADDEX THERAPEUT/ADR (NASDAQ: ADXN ) ADMA Biologics Inc (NASDAQ: ADMA ) Aeglea Bio Therapeutics Inc (NASDAQ: AGLE ) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Affimed NV (NASDAQ: AFMD ) Aileron Therapeutics Inc (NASDAQ: ALRN ) Aimmune Therapeutics Inc (NASDAQ: AIMT ) Akari Therapeutics PLC (NASDAQ: AKTX ) Akcea Therapeutics Inc (NASDAQ: AKCA ) Akero Therapeutics Inc (NASDAQ: AKRO ) Akers Biosciences Inc (NASDAQ: AKER ) Akorn, Inc.","BLCM,BLE,BLUE,BLFS,BNGO",en,Benzinga
2020-03-11 07:03:52-05:00,"The Daily Biotech Pulse: NY State Endorses Mallinckrodt's Opioid Settlement, Kamada To Work On COVID-19 Treatment","Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 10) Arcutis Biotherapeutics Inc (NASDAQ: ARQT ) Aytu Bioscience Inc (NASDAQ: AYTU ) ( announced a deal to distribute COVID-19 test) Centogene NV (NASDAQ: CNTG ) Forty Seven Inc (NASDAQ: FTSV ) Down In The Dumps (Biotech Stocks Hitting 52-week lows on March 10) Accelerate Diagnostics Inc (NASDAQ: AXDX ) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Adaptive Biotechnologies Corp (NASDAQ: ADPT ) ADMA Biologics Inc (NASDAQ: ADMA ) Aeglea Bio Therapeutics Inc (NASDAQ: AGLE ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Affimed NV (NASDAQ: AFMD ) Akari Therapeutics PLC (NASDAQ: AKTX ) Akcea Therapeutics Inc (NASDAQ: AKCA ) Aldeyra Therapeutics Inc (NASDAQ: ALDX ) Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN ) Alkermes Plc (NASDAQ: ALKS ) Allena Pharmaceuticals Inc (NASDAQ: ALNA ) ANCHIANO THERAP/S ADR (NASDAQ: ANCN ) AngioDynamics, Inc. (NASDAQ: ANGO ) ANI Pharmaceuticals Inc (NASDAQ: ANIP ) Anixa Biosciences Inc (NASDAQ: ANIX ) AnPac Bio-Medical Science Co Ltd – ADR (NASDAQ: ANPC ) Aptevo Therapeutics Inc (NASDAQ: APVO ) Aptinyx Inc (NASDAQ: APTX ) Assertio Therapeutics Inc (NASDAQ: ASRT ) Atara Biotherapeutics Inc (NASDAQ: ATRA ) Atossa Therapeutics Inc (NASDAQ: ATOS ) Autolus Therapeutics Ltd – ADR (NASDAQ: AUTL ) AxoGen, Inc Common Stock (NASDAQ: AXGN ) Axovant Gene Therapies Ltd (NASDAQ: AXGT ) Bausch Health Companies Inc (NYSE: BHC ) Bellicum Pharmaceuticals Inc (NASDAQ: BLCM ) BENITEC BIOPHAR/S ADR (NASDAQ: BNTC ) BioLife Solutions Inc (NASDAQ: BLFS ) bluebird bio Inc (NASDAQ: BLUE ) Black Diamond Therapeutics Inc (NASDAQ: BDTX ) Capricor Therapeutics Inc (NASDAQ: CAPR ) Celcuity Inc (NASDAQ: CELC ) Cerecor Inc (NASDAQ: CERC ) Chembio Diagnostics Inc (NASDAQ: CEMI ) Eiger Biopharmaceuticals Inc (NASDAQ: EIGR ) Enochian Biosciences Inc (NASDAQ: ENOB ) Entasis Therapeutics Holdings Inc (NASDAQ: ETTX ) Eton Pharmaceuticals Inc (NASDAQ: ETON ) Evolus Inc (NASDAQ: EOLS ) Exicure Inc (NASDAQ: XCUR ) Eyepoint Pharmaceuticals Inc (NASDAQ: EYPT ) Five Prime Therapeutics Inc (NASDAQ: FPRX ) Gossamer Bio Inc (NASDAQ: GOSS ) Gritstone Oncology Inc (NASDAQ: GRTS ) GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH ) Heron Therapeutics Inc (NASDAQ: HRTX ) Incyte Corporation (NASDAQ: INCY ) INmune Bio Inc (NASDAQ: INMB ) Integra Lifesciences Holdings Corp (NASDAQ: IART ) Invivo Therapeutics Holdings Corp (NASDAQ: NVIV ) Jaguar Health Inc (NASDAQ: JAGX ) Jazz Pharmaceuticals PLC (NASDAQ: JAZZ ) Kura Oncology Inc (NASDAQ: KURA ) Lantheus Holdings Inc (NASDAQ: LNTH ) TapImmune Inc.","BLUE,BLE,BLFS,BLCM",en,Benzinga
2020-03-10 08:19:55-05:00,"The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index","Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 9.) Arcutis Biotherapeutics Inc (NASDAQ: ARQT ) Enzo Biochem, Inc. (NYSE: ENZ ) Centogene NV (NASDAQ: CNTG ) Inovio Pharmaceuticals Inc (NASDAQ: INO ) Spherix Inc (NASDAQ: SPEX ) ( added to Friday's advance on clinching an option agreement for coronavirus treatment) Down In The Dumps (Biotech stocks that hit 52-week lows March 9.) ABIOMED, Inc. (NASDAQ: ABMD ) Acasti Pharma Inc (NASDAQ: ACST ) Achieve Life Sciences Inc (NASDAQ: ACHV ) Acorda Therapeutics Inc (NASDAQ: ACOR ) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Adaptive Biotechnologies Corp (NASDAQ: ADPT ) ADMA Biologics Inc (NASDAQ: ADMA ) Aeglea Bio Therapeutics Inc (NASDAQ: AGLE ) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Affimed NV (NASDAQ: AFMD ) Akers Biosciences Inc (NASDAQ: AKER ) Akorn, Inc. (NASDAQ: AKRX ) Aldeyra Therapeutics Inc (NASDAQ: ALDX ) Alexion Pharmaceuticals, Inc.","BLUE,BLE,BLFS,BLCM",en,Benzinga
2020-02-19 13:53:28-05:00,"bluebird bio Sinks on Earnings, Application Setback",BLUE has shed 40% over the past 12 months,"BLUE,BLE",en,Schaeffers Investment Research
2020-02-18 16:05:00-05:00,bluebird bio Reports Fourth Quarter and Full Year 2019 Financial Results and Highlights Operational Progress,"CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) today reported financial results and business highlights for the fourth quarter and full year ended December 31, 2019. “2019 was truly a transformative year for bluebird, with our first commercial product now launched in Europe and exciting progress across our first four clinical programs and pipeline,” said Nick Leschly, chief bluebird. “Notably, our data in SCD continues to build, and at the ASH annual meeting in December we","BLUE,BLE",en,Business Wire
2020-02-05 08:00:00-05:00,bluebird bio Announces Upcoming Investor Events,"CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will present at the following upcoming investor conferences: 9th Annual SVB Leerink Global Healthcare Conference, Wednesday, February 26, at 2:30 p.m. ET at the Lotte New York Palace, New York, NY Cowen 40th Annual Health Care Conference, Tuesday, March 3, at 8:00 a.m. ET at the Boston Marriott Copley Place, Boston, MA To access the live webcasts of bluebird bio’s presentatio","BLUE,BLE",en,Business Wire
2020-01-27 08:30:00-05:00,Bristol-Myers Squibb is planning to launch 8 drugs in 18 months for everything from cancer to multiple sclerosis. Here's what they are and how the $150 billion pharma giant plans to pull it off.,"The newly combined Bristol-Myers Squibb and Celgene is shaping up to be a formidable company in the pharmaceutical industry. It's now looking at eight upcoming drug launches over the next 12 to 18 months, Bristol-Myers Squibb chief commercial officer Chris Boerner told Business Insider. From treatments that use the body's cells to fight cancer to potential treatments for multiple sclerosis and psoriasis, here's what's ahead for the pharma giant. Click here for more BI Prime stories . When Bristol-Myers Squibb picked up biotech giant Celgene in a deal valued at $74 billion, it formed a formidable company that could become the biggest cancer drugmaker in the world . As a combined company it has the benefit of owning two sets of treatments that have been developed for various diseases, some of which are on the cusp of getting approval. That's teeing BMS up for potentially eight drug launches over the next 12 to 18 months, Chris Boerner, BMS chief commercial officer told Business Insider. ","BLUE,BLE,BMY",en,Business Insider
2020-01-13 06:34:59-05:00,"bluebird bio startet in Deutschland mit der weltweit ersten Markteinführung der Gentherapie Zynteglo(TM) (autologe CD34+-Zellen, die für das ßA-T87Q-Globin-Gen kodieren)","bluebird bio - München (ots) - Zynteglo greift an der genetischen Ursache der transfusionsabhängigen ß-Thalassämie (TDT) an und bietet bestimmten Patienten ab 12 Jahren die Chance, potenziell lebenslang unabhängig von Bluttransfusionen zu …","BLE,BLUE",de,Presseportal.de
2020-01-13 05:00:00-05:00,bluebird bio Announces Launch in Germany of ZYNTEGLO™ (autologous CD34+ cells encoding βA-T87Q-globin gene) Gene Therapy for Patients 12 Years and Older with Transfusion-Dependent β-Thalassemia Who Do Not Have β0/β0 Genotype,"CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) announced the launch in Germany of ZYNTEGLO™ (autologous CD34+ cells encoding βA-T87Q-globin gene), a one-time gene therapy for patients 12 years and older with transfusion-dependent β-thalassemia (TDT) who do not have a β0/β0 genotype, for whom hematopoietic stem cell (HSC) transplantation is appropriate but a human leukocyte antigen (HLA)-matched related HSC donor is not available. This is the first time ZYNTEGLO is commerci","BLE,BLUE",en,Business Wire
2019-12-19 16:05:00-05:00,bluebird bio Announces Investor Events in January,"CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will present at the following upcoming investor conferences in January: Goldman Sachs 12th Annual Healthcare CEOs Unscripted: A View from the Top, Thursday, January 9, at 2:00 p.m. ET at the Goldman Sachs Offices, New York City 38th Annual J.P. Morgan Healthcare Conference, Tuesday, January 14, at 3:00 p.m. PT at the Westin St. Francis Hotel, San Francisco, followed by a ques","BLE,BLUE",en,Business Wire
2019-12-09 18:15:00-05:00,bluebird bio and Bristol-Myers Squibb Present Updated Data from Ongoing Phase 1 Study of BCMA-Targeted CAR T Cell Therapy bb21217 in Relapsed/Refractory Multiple Myeloma at 61st ASH Annual Meeting and Exposition,"CAMBRIDGE, Mass., & PRINCETON, N.J.--(BUSINESS WIRE)--bluebird bio and BMS announce updated results from the ongoing Phase 1 study (CRB-402) of bb21217 in Relapsed and Refractory Multiple Myeloma at ASH","BLE,BLUE",en,Business Wire
2019-12-09 15:51:29-05:00,"5 Top Stock Trades for Tuesday: CHWY, SFIX, SHOP, BLUE, TOL | InvestorPlace","Chewy, Toll Brothers, Stitch Fix, bluebird bio and Shopify were our top stock trades from Monday. Here's a look at the charts.","BLE,BLUE",en,InvestorPlace
2019-12-09 09:16:00-05:00,Bluebird Bio Stock Is Rising on Promising Cancer-Drug Data,Shares took off Monday morning after the company reported data at a medical conference over the weekend that relieved investor anxiety over the company’s experimental cancer drug ide-cel.,"BLE,BLUE",en,Barron's
2019-12-07 14:00:00-05:00,bluebird bio Presents New Data from Ongoing Phase 1/2 HGB-206 Study of LentiGlobin™ Gene Therapy for Sickle Cell Disease (SCD) at 61st ASH Annual Meeting and Exposition,bluebird bio Presents New Data from Ongoing Phase 1/2 HGB-206 Study of LentiGlobin™ Gene Therapy for Sickle Cell Disease (SCD) at ASH Annual Meeting,"BLE,BLUE",en,Business Wire
2019-12-06 16:16:00-05:00,Bristol-Myers Squibb and bluebird bio Announce Positive Top-line Results from the Pivotal Phase 2 KarMMa Study of Ide-cel in Relapsed and Refractory Multiple Myeloma,"PRINCETON, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BMY #BLUE--BMS and bluebird bio Announce Positive Top-line Results from the Pivotal Phase 2 KarMMa Study of Ide-cel in Relapsed and Refractory Multiple Myeloma","BLE,BLUE",en,Business Wire
2019-12-02 07:30:00-05:00,bluebird bio Announces Live Webcast to Review Clinical Data Presented at the American Society of Hematology (ASH) Annual Meeting,"CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) today announced that the company will host a live webcast on December 9, 2019 at 8:00 p.m. ET to review clinical data presented at the 61st American Society of Hematology Annual Meeting and Exposition. Investors may listen to the call by dialing (844) 825-4408 from locations in the United States or +1 (315) 625-3227 from outside the United States. Please refer to conference ID number 3052538. To access the live webcast of blue","BLE,BLUE",en,Business Wire
2019-11-26 09:19:00-05:00,Bluebird Bio Stock Is Rising as Analyst Cites Room for Gains,"Analysts at SVB Leerink upgraded bluebird bio to Outperform, saying that its recent downturn creates an opportunity to buy.","BLE,BLUE",en,Barron's
2019-11-12 07:00:00-05:00,bluebird bio and Forty Seven Announce a Research Collaboration to Study an All Antibody Conditioning Regimen for Use in Combination with Autologous Lentiviral Vector Hematopoietic Stem Cell Gene Therapy,"CAMBRIDGE, Mass. & MENLO PARK, Calif.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) and Forty Seven, Inc. (Nasdaq:FTSV) announced today that they have entered into a research collaboration to pursue clinical proof-of-concept for Forty Seven’s novel antibody-based conditioning regimen, FSI-174 (anti-cKIT antibody) plus magrolimab (anti-CD47 antibody), with bluebird’s ex vivo lentiviral vector hematopoietic stem cell (LVV HSC) gene therapy platform. This collaboration will focus on a condit","BLE,BLUE",en,Business Wire
2019-11-08 08:14:09-05:00,"The Daily Biotech Pulse: Therapix Calls Off Merger, Alimera's Reverse Split, 2 Biotechs To Debut","The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Nov. 7.) Collegium Pharmaceutical Inc (NASDAQ: COLL ) (reacted to third-quarter results released after the market close Wednesday) Deciphera Pharmaceuticals Inc (NASDAQ: DCPH ) DexCom, Inc. (NASDAQ: DXCM ) (reacted to its better-than-expected third-quarter results ) INNATE PHARMA S/S ADR (NASDAQ: IPHA ) Rapt Therapeutics Inc (NASDAQ: RAPT ) (went public Oct. 31) Viela Bio Inc (NASDAQ: VIE ) (went public Oct. 3) XOMA Corp (NASDAQ: XOMA ) Down In The Dumps (Biotech stocks that hit 52-week lows Nov. 7.) Allena Pharmaceuticals Inc (NASDAQ: ALNA ) (reported positive results from two studies evaluating its reloxaliase in high-risk patients with enteric hyperoxaluria and advanced chronic kidney disease) Auris Medical Holding Ltd (NASDAQ: EARS ) bluebird bio Inc (NASDAQ: BLUE ) Caladrius Biosciences Inc (NASDAQ: CLBS ) (reacted to its third-quarter results) CENTOGENE ORD (NASDAQ: CNTG ) (went public Thursday) Cocrystal Pharma Inc (NASDAQ: COCP ) Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP ) Helius Medical Technologies Inc (NASDAQ: HSDT ) Infinity Pharmaceuticals Inc.","BLUE,BLE",en,Benzinga
2019-11-07 05:38:02-05:00,"The Daily Biotech Pulse: Obseva Sinks On Adverse Clinical Readout, BioNano Surges On Saphyr Adoption, 2 IPOs","Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 6) Agile Therapeutics Inc (NASDAQ: AGRX )(follow-on rally following positive Adcom verdict for Twirla) Constellation Pharmaceuticals Inc (NASDAQ: CNST )(announced positive results from a Phase 2 trial of CPI-0610 in combination with Jakafi in myelofibrosis) Exagen Inc (NASDAQ: XGN ) INNATE PHARMA S/S ADR (NASDAQ: IPHA ) Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA ) Repro-Med Systems, Inc. (NASDAQ: KRMD ) TFF Pharmaceuticals Inc (NASDAQ: TFFP ) Viela Bio Inc (NASDAQ: VIE ) (IPOed Oct. 3) ZEALAND PHARMA/S ADR (NASDAQ: ZEAL ) Down In The Dumps (Biotech stocks hitting 52-week lows on Nov. 6) AcelRx Pharmaceuticals Inc (NASDAQ: ACRX ) Achieve Life Sciences Inc (NASDAQ: ACHV ) AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO ) Biocept Inc (NASDAQ: BIOC ) bluebird bio Inc (NASDAQ: BLUE ) Cocrystal Pharma Inc (NASDAQ: COCP ) Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP ) Cyclerion Therapeutics Inc (NASDAQ: CYCN ) Diffusion Pharmaceuticals Inc (NASDAQ: DFFN ) Exelixis, Inc.","BLUE,BLE,BNGO",en,Benzinga
2019-11-06 09:05:36-05:00,bluebird bio : to Present New Data from Gene and Cell Therapy Programs at 61st American Society of Hematology Annual Meeting and Exposition | MarketScreener,"Nov. 6, 2019-- bluebird bio, Inc. announced today that new and updated data from its investigational gene and cell therapy programs for multiple myeloma, sickle cell disease and… | November 6, 2019","BLE,BLUE",en,MarketScreener
2019-11-06 09:00:00-05:00,bluebird bio to Present New Data from Gene and Cell Therapy Programs at 61st American Society of Hematology Annual Meeting and Exposition,"CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) announced today that new and updated data from its investigational gene and cell therapy programs for multiple myeloma, sickle cell disease (SCD) and transfusion-dependent β-thalassemia (TDT) will be presented at the 61st American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, Florida, December 7 - 10. bluebird bio will present updated safety and efficacy data from the ongoing Phase 1 clinical study (CRB","BLE,BLUE",en,Business Wire
2019-10-31 15:05:00-05:00,bluebird bio Reports Third Quarter 2019 Financial Results and Highlights Operational Progress,"CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) today reported financial results and business highlights for the third quarter ended September 30, 2019. “During the third quarter we advanced our country-by-country launch plans in Europe and, with the recent approval of the commercial drug product manufacturing specifications for ZYNTEGLO, we moved one step closer to our goal of treating patients suffering from TDT in early 2020,” said Nick Leschly, chief bluebird. “Also thi","BLE,BLUE",en,Business Wire
2019-10-25 06:12:03-05:00,"The Daily Biotech Pulse: Melinta Crosses FDA Hurdle But Sees Liquidity Pushback, Positive Readout For Aclaris Wart Drug","Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Oct. 24) AstraZeneca plc (NYSE: AZN ) (reacted to a beat-and-raise quarter) Edwards Lifesciences Corp (NYSE: EW )( reported better-than-expected third-quarter results) Frequency Therapeutics Inc (NASDAQ: FREQ ) (IPOed Oct. 3) GlaxoSmithKline plc (NYSE: GSK )(FDA approved expanded use of Zejula) Novo Nordisk A/S (NYSE: NVO ) Down In The Dumps (Biotech stocks hitting 52-week lows on Oct. 24) Acorda Therapeutics Inc NASDAQ: ACOR) (announced restructuring plan, including the elimination of 25% of its workforce) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP ) bluebird bio Inc (NASDAQ: BLUE ) (announced resignation of chief strategy officer) Brickell Biotech Inc (NASDAQ: BBI ) CytomX Therapeutics Inc (NASDAQ: CTMX ) Diffusion Pharmaceuticals Inc (NASDAQ: DFFN ) Gritstone Oncology Inc (NASDAQ: GRTS ) KemPharm Inc (NASDAQ: KMPH ) MacroGenics Inc (NASDAQ: MGNX ) Midatech Pharma PLC-ADR (NASDAQ: MTP ) OpGen Inc (NASDAQ: OPGN ) )(announcing pricing of previously-announced underwritten common stock offering) Opko Health Inc. (NASDAQ: OPK )(announced a follow-on offering) Orgenesis Inc (NASDAQ: ORGS ) Rexahn Pharmaceuticals, Inc. (NASDAQ: REXN ) Titan Medical Inc. (NASDAQ: TMDI ) Stocks In Focus Melinta Gets FDA Nod For Baxdela Label Expansion; Launch to Be Delayed Due to Liquidity Concerns Melinta Therapeutics Inc (NASDAQ: MLNT ) announced FDA approval for Baxdela for the treatment of adult patients with community-acquired bacterial pneumonia, or CABP, caused by designated succeptible bacteria.","BLUE,BLE",en,Benzinga
2019-10-22 06:30:00-05:00,European Medicines Agency Approves Refined Commercial Manufacturing Specifications for ZYNTEGLO™,"bluebird bio, Inc. (BLUE) announced today that the European Medicines Agency (EMA) approved the refined commercial drug product manufacturing specifications for ZYNTEGLO™ (autologous CD34+ cells encoding βA-T87Q-globin gene), a one-time gene therapy for patients 12 years and older with transfusion-dependent","BLE,BLUE",en,ACI Information Group
2019-10-15 10:01:11-05:00,Is bluebird bio Inc (BLUE) Going To Burn These Hedge Funds ?,"Is bluebird bio Inc (NASDAQ:BLUE) a good investment right now? We check hedge fund and billionaire investor sentiment before delving into hours of research. Hedge funds spend millions of dollars on Ivy League graduates, expert networks, and get tips from investment bankers and industry insiders. Sure","BLE,BLUE",en,ACI Information Group
2019-10-04 06:32:50-05:00,"The Daily Biotech Pulse: Arbutus Halts Hepatitis B Study, Positive Readout For MEI Pharma's Blood Cancer Drug, Ovid Offering","Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week lows on Oct. 3) Aprea Therapeutics Inc (NASDAQ: APRE ) (IPOed on Thursday) Viela Bio Incn (NASDAQ: VIE ) (IPOed on Thursday) Down In The Dumps (Biotech stocks hitting 52-week lows on Oct. 3) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP ) Alpine Immune Sciences Inc (NASDAQ: ALPN ) bluebird bio Inc . (NASDAQ: BLUE ) Corvus Pharmaceuticals Inc (NASDAQ: CRVS ) DelMar Pharmaceuticals Inc (NASDAQ: DMP ) Eloxx Pharmaceuticals Inc (NASDAQ: ELOX ) Erytech Pharma SA (NASDAQ: ERYP ) Frequency Therapeutics Inc (NASDAQ: FREQ )(IPOed on Thursday) Fulcrum Therapeutics Inc (NASDAQ: FULC ) Jaguar Health Inc (NASDAQ: JAGX ) Karuna Therapeutics Inc (NASDAQ: KRTX ) Kiniksa Pharmaceuticals Ltd (NASDAQ: KNSA ) Madrigal Pharmaceuticals Inc (NASDAQ: MDGL ) Neuralstem, Inc. (NASDAQ: CUR ) Obseva SA (NASDAQ: OBSV ) Onconova Therapeutics Inc (NASDAQ: ONTX ) RA Medical Systems Inc (NYSE: RMED ) Sierra Oncology Inc (NASDAQ: SRRA ) Titan Pharmaceuticals, Inc. (NASDAQ: TTNP ) Trinity Biotech plc (NASDAQ: TRIB ) Viveve Medical Inc (NASDAQ: VIVE ) Stocks In Focus Arbutus Halts Hepatitis B Drug Study Arbutus Biopharma Corp (NASDAQ: ABUS ) decided to discontinue the development of AB-506, an oral capsid inhibitor, which was being evaluated in a Phase 1a/1b trial for the treatment …","BLUE,BLE",en,Benzinga
2019-10-01 12:48:06-05:00,"Stifel Bullish On Iovance And Fate Therapeutics, Neutral On Bluebird Bio","Stifel initiated coverage on a trio of oncology-focused biotechs Tuesday, recommending buying two and staying sidelined on a third. The Analyst Benjamin Burnett initiated coverage of: bluebird bio Inc NASDAQ: BLUE) with a Hold rating and $109 price target. Iovance Biotherapeutics Inc NASDAQ: IOVA) with a Buy rating and $27 price target Fate Therapeutics Inc (NASDAQ: FATE ) with a Buy rating and $27 price target Gene Therapy Launch, Multiple Myeloma Uncertainty Temper Optimism On Bluebird The slow launch anticipated for Zynteglo, bluebird bio's gene therapy to treat transfusion-dependent β-thalassemia, and competitive programs imparting uncertainty to its multiple myeloma market have left Stifel wary of bluebird bio. These concerns are likely to be mitigated by a neutral stance on Lenti-D in cerebral adrenoleukodystrophy, an inherited neurological disorder, and Burnett's confidence … Full story available on Benzinga.com","BLE,BLUE",en,Benzinga
2019-07-25 09:33:31-05:00,Analysts Estimate Bluebird Bio (BLUE) to Report a Decline in Earnings: What to Look Out for,Bluebird (BLUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.,"BLE,BLUE",en,Zacks Investment Research
2019-06-04 15:16:00-05:00,bluebird's Zynteglo Gets EU Conditional Marketing Approval,"bluebird bio (BLUE) announces that the EC has granted conditional marketing authorization to Zynteglo, its first gene therapy, for patients aged 12 years or older with TDT, who do not have a specific genotype.","BLE,BLUE",en,Zacks Investment Research
2019-05-29 19:21:00-05:00,Cramer Remix: I think this is a great spec play that could get acquired,Jim Cramer explains that bluebird bio's technology offerings make it attractive for a potential takeover.,"BLE,BLUE",en,CNBC
2019-05-29 18:23:00-05:00,Cramer Remix: I think this is a great spec play,Jim Cramer explains that bluebird bio's technology offerings make it attractive for a potential takeover.,"BLE,BLUE",en,CNBC
2019-05-15 09:49:00-05:00,Bluebird Bio’s Pricing Plan Worries One Biotech Analyst. Here’s Why.,Wedbush’s David Nierengarten downgraded his rating on Bluebird to Neutral from Outperform,"BLE,BLUE",en,Barron's
2019-05-15 06:23:06-05:00,Bluebird bio downgraded to neutral from outperform at Wedbush,"This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news.","BLE,BLUE",en,MarketWatch
2019-05-08 07:12:00-05:00,bluebird bio Flies Forward,An approval for Zynteglo is imminent.,"BLE,BLUE",en,The Motley Fool
2019-05-02 17:45:04-05:00,"Bluebird Bio (BLUE) Reports Q1 Loss, Tops Revenue Estimates","Bluebird (BLUE) delivered earnings and revenue surprises of -6.79% and 2.58%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?","BLE,BLUE",en,Zacks Investment Research
2019-05-02 15:56:58-05:00,"bluebird bio misses by $0.16, misses on revenue",bluebird bio (BLUE): Q1 GAAP EPS of -$2.99 misses by $0.16. Revenue of $12.5M (-21.7% Y/Y) misses by $2.99M. Press Release,"BLE,BLUE",en,Seeking Alpha
2019-04-24 09:33:01-05:00,Bluebird Bio (BLUE) Expected to Beat Earnings Estimates: Should You Buy?,Bluebird (BLUE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.,"BLUE,BLE",en,Zacks Investment Research
2019-04-17 16:15:15-05:00,Here's Why Shares of bluebird bio Slumped Today,No-news anxiety-selling seems to be to blame for the biotech's woes.,"BLE,BLUE",en,The Motley Fool
2019-04-11 17:41:43-05:00,bluebird bio's CHMP Response Lays Ground Work For Its First Gene Therapy Approval,bluebird bio's Zynteglo receives positive CHMP opinion for approval of Zynteglo to treat transfusion dependent beta-thalassemia patients. The European Commissio,"BLUE,BLE",en,Seeking Alpha
2019-04-09 09:52:00-05:00,Why bluebird bio Could Deliver Miracles to Genetic Disease Patients,CAR-T therapies have the potential to work wonders in hospitals and in your portfolio.,"BLUE,BLE",en,The Motley Fool
2019-03-29 06:47:42-05:00,UPDATE 1-EMA panel recommends approval of Bluebird Bio's first gene therapy,"A European Medicines Agency panel on Friday recommended a conditional marketing approval for a gene therapy from Bluebird Bio Inc as a genetic blood disorder treatment, setting the stage for the U.S. biotech to win its first regulatory nod.","BLUE,BLE",en,Reuters
2019-03-29 06:36:00-05:00,EMA panel recommends approval of Bluebird Bio's first gene therapy,"A European Medicines Agency panel on Friday recommended a conditional marketing approval for a gene therapy from Bluebird Bio Inc as a genetic blood disorder treatment, setting the stage for the U.S. biotech to win its first regulatory nod.","BLUE,BLE",en,Reuters
2019-03-22 08:03:27-05:00,Bluebird bio opens new facility in North Carolina,No summary available.,"BLE,BLUE",en,Seeking Alpha
2019-02-12 05:30:00-05:00,Celgene and Other Biotech Stocks Could Get a Boost From Exchange-Traded Funds Buying In,"Jefferies analyst Michael Yee says the sector’s comeback could force exchange-traded funds to start buying up the stocks again. Big biotech ETF holdings such as Sage Therapeutics, Celgene, and bluebird bio are running well ahead of the market so far this year.",BLE,en,Barron's
2019-02-11 06:52:48-05:00,New CFO at Bluebird bio,No summary available.,"BLUE,BLE",en,Seeking Alpha
2019-02-11 06:52:48-05:00,New CFO at Bluebird bio,No summary available.,BLE,en,Seeking Alpha
2019-02-05 10:00:00-05:00,bluebird bio's Pricing Strength Expands Their Potential,No summary available.,"BLUE,BLE",en,Seeking Alpha
2019-02-05 10:00:00-05:00,bluebird bio's Pricing Strength Expands Their Potential,No summary available.,"BLE,BLUE",en,Seeking Alpha
2019-02-05 10:00:00-05:00,bluebird bio's Pricing Strength Expands Their Potential,No summary available.,BLE,en,Seeking Alpha
2019-01-28 18:10:40-05:00,Crispr Therapeutics -6% as Goldman downgrade cites battle with Bluebird Bio,No summary available.,"BLUE,BLE",en,Seeking Alpha
2019-01-28 18:10:40-05:00,Crispr Therapeutics -6% as Goldman downgrade cites battle with Bluebird Bio,No summary available.,"BLE,BLUE",en,Seeking Alpha
2019-01-28 18:10:40-05:00,Crispr Therapeutics -6% as Goldman downgrade cites battle with Bluebird Bio,No summary available.,BLE,en,Seeking Alpha
2019-01-07 13:13:22-05:00,Bluebird bio up 8% on CAR-T development deal with Inhibrx,No summary available.,"BLUE,BLE",en,Seeking Alpha
2019-01-07 13:13:22-05:00,Bluebird bio up 8% on CAR-T development deal with Inhibrx,No summary available.,"BLE,BLUE",en,Seeking Alpha
